All Articles

A new survey shows Asians value independence over inheritance, yet a massive gap between intention and action threatens to derail their plans for self-reliance.

Elixiron's enrupatinib shows promise in targeting neuroinflammation, with early data suggesting cognitive benefits and a new biomarker-guided path for therapy.

The recent acquisition of a thriving San Diego shopping center is more than a real estate deal. It's a test case for an ambitious plan to remake suburbia.

As Singapore's non-bank lending space heats up, Bizcap unveils a lucrative loyalty program. Is this a game-changer for SME funding or just a costly gambit?

Industrial giants struggle to scale automation beyond pilot projects. A new CEO playbook from ASI, backed by millions of autonomous miles, offers a blueprint.

As Ottawa rolls out a new food strategy, Pamela Cox examines whether it can fix a broken system of soaring costs and deep-seated insecurity for millions.

While firms spend billions on tech, a new book argues the biggest data breaches stem from leadership gaps and process failures. Is your boardroom the real front line?

For decades, patients with a rare autoimmune anemia faced a cycle of steroids and relapse. New data on a targeted therapy may finally offer a durable solution.

As FIFA World Cup 2026 kicks off, Hisense is executing a masterclass in market disruption, using the global stage to redefine the TV landscape with RGB MiniLED.

A Korean materials firm just won a top Boeing award. We go beyond the press release to reveal how it’s fortifying global supply chains and reshaping Asia's aerospace hub.

A new financing vehicle aims to de-risk high-integrity carbon projects, but can this "carbon streaming" model unlock Central Asia's climate potential?

FCPT's latest acquisition seems minor, but it reveals a powerful strategy for navigating economic uncertainty by targeting essential, service-based real estate.

As hospitals face a ballooning $55B annual IT bill, Vizient's latest acquisition signals a major offensive to control costs beyond the traditional supply chain.

After a decade-long hiatus from major global partnerships and a recent financial overhaul, Oriflame is betting on spectacle. But is this a savvy brand revival or a costly distraction?

JAB's ~$1.8B sale of its final KDP stake isn't just an exit; it's a masterclass in capital reallocation towards a focused consumer brand empire.

A new FDA-designated device aims to filter a deadly protein from the blood of sepsis patients. Can this novel approach finally conquer a global health crisis?

Northfield shareholders face a July 10 deadline to pick cash or stock in a merger tied to a complex bank conversion set to reshape the NJ/NY banking landscape.

Amid market uncertainty, Vornado's $1.1B valuation deal for Park Avenue Plaza signals a bullish long-term view on New York City's trophy office space.

With a $20M Series A led by L Catterton, Dr. Muneeb Shah's REMEDY is disrupting skincare. Here's how accessible science is winning over consumers.

AM Best's recent 'Excellent' rating for Weston2038's notes is more than a headline. It's a vote of confidence in a hidden world of financial architecture.